进行性核上性麻痹的治疗及康复进展

doi:10.3969/j.issn.1006-9771.2017.02.011

Abstract

Abstract: Progressive supranuclear palsy (PSP) is a rare neurodegenerative disease. The etiology and pathogenesis are still unclear. Nowadays there is a lack of an effective molecular marker which can effectively assist the early diagnosis and prognosis of this disease. This article reviewed the pathological anatomy, diagnostic criteria, subtypes and clinical manifestations, imaging studies, scales evaluation, treatment and rehabilitation, complications and risk factors of PSP. Patients with PSP should be managed by a multidisciplinary team. The management of PSP should include the rehabilitation of disorder and palliative treatment, as well as support and education, to improve the quality of life for patients and their caregivers.

Key words: progressive supranuclear palsy, treatment, rehabilitation, review

CLC Number:

R742.5

LIN Wei, CHEN Ning-yuan. Treatments and Rehabilitation for Progressive Supranuclear Palsy (review)[J]. 《Chinese Journal of Rehabilitation Theory and Practice》, 2017, 23(2): 173-178.

References

[1] Ling H. Clinical approach to progressive supranuclear palsy [J]. J Mov Disord, 2016, 9(1): 3-13.
[2] Kaat DL, Chiu WZ, Boon AJ, et al. Recent advances in progressive supranuclear palsy: a review [J]. Curr Alzheimer Res, 2011, 8(3): 295-302.
[3] Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop [J]. Neurology, 1996, 47(1): 1-9.
[4] 中华医学会神经病学分会帕金森病及运动障碍学组,中国医师协会神经内科医师分会帕金森病及运动障碍专业委员会. 中国进行性核上性麻痹临床诊断标准[J]. 中华神经科杂志, 2016, 49(4): 272-276.
[5] Nath U, Thomson R, Wood R, et al. Population based mortality and quality of death certification in progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) [J]. J Neurol Neurosurg Psychiatry, 2005, 76(4): 498-502.
[6] Ling H, Massey LA, Lees AJ, et al. Hypokinesia without decrement distinguishes progressive supranuclear palsy from Parkinson's disease [J]. Brain, 2012, 135(Pt 4): 1141-1153.
[7] Respondek G, Stamelou M, Kurz C, et al. The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases [J]. Mov Disord, 2014, 29(14): 1758-1766.
[8] Facheris MF, Maniak S, Scaravilli F, et al. Pure akinesia as initial presentation of PSP: a clinicopathological study [J]. Parkinsonism Relat Disord, 2008, 14(6): 517-519.
[9] Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration [J]. Neurology, 2013, 80(5): 496-503.
[10] Josephs KA, Duffy JR. Apraxia of speech and nonfluent aphasia: a new clinical marker for corticobasal degeneration and progressive supranuclear palsy [J]. Curr Opin Neurol, 2008, 21(6): 688-692.
[11] Hassan A, Parisi JE, Josephs KA. Autopsy-proven progressive supranuclear palsy presenting as behavioral variant frontotemporal dementia [J]. Neurocase, 2012, 18(6): 478-488.
[12] Kanazawa M, Tada M, Onodera O, et al. Early clinical features of patients with progressive supranuclear palsy with predominant cerebellar ataxia [J]. Parkinsonism Relat Disord, 2013, 19(12): 1149-1151.
[13] Liscic RM, Srulijes K, Gröger A, et al. Differentiation of progressive supranuclear palsy: clinical, imaging and laboratory tools [J]. Acta Neurol Scand, 2013, 127(5): 362-370.
[14] Quattrone A, Nicoletti G, Messina D, et al. MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy [J]. Radiology, 2008, 246(1): 214-221.
[15] 朱银伟,孙永安,陈俊,等. 磁共振帕金森指数对进行性核上性麻痹的诊治提示[J]. 中国神经精神疾病杂志, 2012, 38(9):547-550.
[16] Wang G, Wang J, Zhan J, et al. Quantitative assessment of cerebral gray matter density change in progressive supranuclear palsy using voxel based morphometry analysis and cerebral MR T1-weighted FLAIR imaging [J]. J Neurol Sci, 2015, 359(1-2): 367-372.
[17] Golbe LI, Ohman-Strickland PA. A clinical rating scale for progressive supranuclear palsy [J]. Brain, 2007, 130(Pt 6): 1552-1565.
[18] Hall DA, Forjaz MJ, Golbe LI, et al. Scales to assess clinical features of progressive supranuclear palsy: MDS task force report [J]. Mov Disord Clin Pract, 2015, 2(2): 127-134.
[19] Ghosh BC, Carpenter RH, Rowe JB. A longitudinal study of motor, oculomotor and cognitive function in progressive supranuclear palsy [J]. PLoS One, 2013, 8(9): e74486.
[20] Liepelt I, Gaenslen A, Godau J, et al. Rivastigmine for the treatment of dementia in patients with progressive supranuclear palsy: Clinical observations as a basis for power calculations and safety analysis [J]. Alzheimers Dement, 2010, 6(1): 70-74.
[21] Stamelou M, de Silva R, Arias-Carrión O, et al. Rational therapeutic approaches to progressive supranuclear palsy [J]. Brain, 2010, 133(Pt 6): 1578-1590.
[22] Lamb R, Rohrer JD, Lees AJ, et al. Progressive supranuclear palsy and corticobasal degeneration: pathophysiology and treatment options [J]. Curr Treat Options Neurol, 2016, 18(9): 42.
[23] Daniele A, Moro E, Bentivoglio AR. Zolpidem in progressive supranuclear palsy [J]. N Engl J Med, 1999, 341(7): 543-544.
[24] Chang AY, Weirich E. Trial of zolpidem, eszopiclone, and other GABA agonists in a patient with progressive supranuclear palsy [J]. Case Rep Med, 2014, 2014: 107064.
[25] Litvan I, Phipps M, Pharr VL, et al. Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy [J]. Neurology, 2001, 57(3): 467-473.
[26] Boxer AL, Lang AE, Grossman M, et al. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial [J]. Lancet Neurol, 2014, 13(7): 676-685.
[27] Tolosa E, Litvan I, Höglinger GU, et al. A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy [J]. Mov Disord, 2014, 29(4): 470-478.
[28] Apetauerova D, Scala SA, Hamill RW, et al. CoQ10 in progressive supranuclear palsy: A randomized, placebo-controlled, double-blind trial [J]. Neurol Neuroimmunol Neuroinflamm, 2016, 3(5): e266.
[29] Nuebling G, Hensler M, Paul S, et al. PROSPERA: a randomized, controlled trial evaluating rasagiline in progressive supranuclear palsy [J]. J Neurol, 2016, 263(8): 1565-1574.
[30] Choi SW, Park KB, Woo SK, et al. Treatment of progressive supranuclear palsy with autologous adipose tissue-derived mesenchymal stem cells: a case report [J]. J Med Case Rep, 2014, 8: 87.
[31] Giordano R, Canesi M, Isalberti M, et al. Autologous mesenchymal stem cell therapy for progressive supranuclear palsy: translation into a phase I controlled, randomized clinical study [J]. J Transl Med, 2014, 12: 14.
[32] Servello D, Zekaj E, Saleh C, et al. Long-term follow-up of deep brain stimulation of peduncolopontine nucleus in progressive supranuclear palsy: report of three cases [J]. Surg Neurol Int, 2014, 5(Suppl 8): S416-S420.
[33] Izzo KL, DiLorenzo P, Roth A. Rehabilitation in progressive supranuclear palsy: case report [J]. Arch Phys Med Rehabil, 1986, 67(7): 473-476.
[34] Zampieri C, Di FRP. Balance and eye movement training to improve gait in people with progressive supranuclear palsy: quasi-randomized clinical trial [J]. Phys Ther, 2008, 88(12): 1460-1473.
[35] Sale P, Castiglioni D, De Pandis MF, et al. The Lee Silverman Voice Treatment (LSVT ® ) speech therapy in progressive supranuclear palsy [J]. Eur J Phys Rehabil Med, 2015, 51(5): 569-574.
[36] Sale P, Stocchi F, Galafate D, et al. Effects of robot assisted gait training in progressive supranuclear palsy (PSP): a preliminary report [J]. Front Hum Neurosci, 2014, 8: 207.
[37] Suteerawattananon M, MacNeill B, Protas EJ. Supported treadmill training for gait and balance in a patient with progressive supranuclear palsy [J]. Phys Ther, 2002, 82(5): 485-495.
[38] Steffen TM, Boeve BF, Petersen CM, et al. Long-term exercise training for an individual with mixed corticobasal degeneration and progressive supranuclear palsy features: 10-year case report follow-up [J]. Phys Ther, 2014, 94(2): 289-296.
[39] Seamon B, DeFranco M, Thigpen M. Use of the Xbox Kinect virtual gaming system to improve gait, postural control and cognitive awareness in an individual with progressive supranuclear palsy [J]. Disabil Rehabil, 2017, 39(7): 721-726.
[40] Hanson WR, Metter EJ. DAF as instrumental treatment for dysarthria in progressive supranuclear palsy: a case report [J]. J Speech Hear Disord, 1980, 45(2): 268-276.
[41] Boulogne S, Le CF, Bation R, et al. Repetitive transcranial magnetic stimulation can alleviate treatment-resistant depression in patients with progressive supranuclear palsy [J]. Parkinsonism Relat Disord, 2015, 21(9): 1113-1114.
[42] Dunlop SR, Kent VP, Lashley M, et al. The cure PSP care guide: a telephonic nursing intervention for individuals and families living with progressive supranuclear palsy [J]. J Neurosci Nurs, 2016, 48(2): 105-106.
[43] Golbe LI, Davis PH, Schoenberg BS, et al. Prevalence and natural history of progressive supranuclear palsy [J]. Neurology, 1988, 38(7): 1031-1034.
[44] Oropesa-Ruiz JM, Huertas-Fernández I, Jesús S, et al. Low serum uric acid levels in progressive supranuclear palsy [J]. Mov Disord, 2016, 31(3): 402-405.
[45] Tomita S, Oeda T, Umemura A, et al. Impact of aspiration pneumonia on the clinical course of progressive supranuclear palsy: a retrospective cohort study [J]. PLoS One, 2015, 10(8): e0135823.
[46] Nozaki I, Kato-Motozaki Y, Ikeda T, et al. Aspiration pneumonia and bronchopneumonia in progressive supranuclear palsy treated with Qing Fei Tang: two case reports [J]. J Med Case Rep, 2015, 9: 67.

Treatments and Rehabilitation for Progressive Supranuclear Palsy (review)

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Metrics

Comments

Recommended 0

[1]	SHAO Weiting, LEI Jianghua. Effect of response interruption and redirection as a behavioral intervention on vocal stereotypy in children with autism spectrum disorder: a scoping review [J]. 《Chinese Journal of Rehabilitation Theory and Practice》, 2024, 30(1): 10-20.
[2]	LUO Lihua, WANG Yusheng, LI Jianfeng, DONG Jige. Effect of early postoperative comprehensive rehabilitation on children and youth with supracondylar fracture of humerus complicated with ulnar nerve injury [J]. 《Chinese Journal of Rehabilitation Theory and Practice》, 2024, 30(1): 105-110.
[3]	WANG Zihao, LI Xinhua, JIANG Huiping, GUO Sainan, LIANG Qiuman, SHI Tingqi. Short-term knee function after total knee arthroplasty and related factors [J]. 《Chinese Journal of Rehabilitation Theory and Practice》, 2024, 30(1): 111-118.
[4]	WANG Hangyu, GE Keke, FAN Yonghong, DU Lilu, ZOU Min, FENG Lei. Effect of active music therapy on cognitive function for older adults with cognitive impairment: a systematic review based on ICD-11 and ICF [J]. 《Chinese Journal of Rehabilitation Theory and Practice》, 2024, 30(1): 36-43.
[5]	WEN Jianing, JIN Qiuyan, ZHANG Qi, LI Jie, SI Qi. Effect of cognitively engaging physical activity on developing executive function of children and adolescents: a systematic review based on ICF [J]. 《Chinese Journal of Rehabilitation Theory and Practice》, 2024, 30(1): 44-53.
[6]	GE Keke, FAN Yonghong, WANG Hangyu, DU Lilu, LI Changjiang, ZOU Min. Health benefit of mindfulness intervention for older adults with insomnia disorders: a systematic review [J]. 《Chinese Journal of Rehabilitation Theory and Practice》, 2024, 30(1): 54-60.
[7]	CHEN Junwen, CHEN Qian, CHEN Cheng, LI Shuyue, LIU Lingling, WU Cunshu, GONG Xiang, LU Jun, XU Guangxu. Effect of modified Baduanjin exercise on cardiopulmonary function, motor function and activities of daily living for stroke patients [J]. 《Chinese Journal of Rehabilitation Theory and Practice》, 2024, 30(1): 74-80.
[8]	ZHANG Jingya, ZOU Min, SUN Hongwei, SUN Changlong, ZHU Juntong. Effect of psychological intervention on anxiety or depression in children and adolescents with hearing impairment: a systematic review [J]. 《Chinese Journal of Rehabilitation Theory and Practice》, 2023, 29(9): 1004-1011.
[9]	WANG Junyu, YANG Yong, YUAN Xun, XIE Ting, ZHUANG Jie. Effect of high-intensity interval training on executive function for healthy children and adolescents: a systematic review [J]. 《Chinese Journal of Rehabilitation Theory and Practice》, 2023, 29(9): 1012-1020.
[10]	WEI Xiaowei, YANG Jian, WEI Chunyan. Psychological and behavioral benefits of adapted yoga exercise for children with autism spectrum disorder in special education schools: a systematic review [J]. 《Chinese Journal of Rehabilitation Theory and Practice》, 2023, 29(9): 1021-1028.
[11]	YANG Yaru, YANG Jian. School-based physical activity-related health services and their health benefits within the World Health Organization health-promoting school framework: a systematic review of systematic reviews [J]. 《Chinese Journal of Rehabilitation Theory and Practice》, 2023, 29(9): 1040-1047.
[12]	WANG He, HAN Liang, KAN Mengfan, YU Shaohong. Efficacy of electrical stimulation on shoulder-hand syndrome after stroke: a systematic review and meta-analysis [J]. 《Chinese Journal of Rehabilitation Theory and Practice》, 2023, 29(9): 1048-1056.
[13]	SHI Jiawei, LI Lingyu, YANG Haojie, WANG Qinlu, ZOU Haiou. Effect of preoperative prerehabilitation training on total knee arthroplasty: a systematic review of systematic reviews [J]. 《Chinese Journal of Rehabilitation Theory and Practice》, 2023, 29(9): 1057-1064.
[14]	ZOU Yucong, ZHOU Jing, LIN Weiming, LI Dongxia, WANG Juan, WANG Yuqi, WANG Yulong. Treatments for prolonged disorder of consciousness in recent five years: a visualized analysis [J]. 《Chinese Journal of Rehabilitation Theory and Practice》, 2023, 29(9): 1065-1071.
[15]	CAI Huanian, FEI Sixian, ZHANG Yichen, SUN Qing, GUO Shuai, SONG Tao. Motion assistance analysis for robot-assisted tele-rehabilitation based on bilateral admittance control [J]. 《Chinese Journal of Rehabilitation Theory and Practice》, 2023, 29(9): 1104-1109.